Tarsus Pharmaceuticals, Inc. SEC Filings

Tarsus Pharmaceuticals (TARS) filed an 8-K stating it furnished a press release reporting results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.

The information was furnished under Item 2.02 and is not deemed filed for liability purposes under Section 18. The filing was signed by Jeffrey Farrow, Chief Financial Officer and Chief Strategy Officer.

Tarsus Pharmaceuticals (TARS) reporting person Bobak R. Azamian, who serves as President/CEO and Board Chair, disclosed insider transactions on a Form 4. On 09/24/2025 the reporting person sold 6,000 shares of common stock in automatic transactions under a Rule 10b5-1 trading plan adopted December 12, 2024, at a weighted average price of $55.37 (sales ranged from $55.19 to $55.93). After the reported transactions the filing shows 812,106 shares beneficially owned indirectly (held in the Bobak Azamian Living Trust, of which he is trustee with voting and dispositive power) and 53,635 shares shown as disposed on a separate line. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.

Tarsus Pharmaceuticals (TARS) notice shows a proposed sale under Rule 144 of 6,000 common shares through Merrill Lynch, planned for 09/24/2025. The filing reports an aggregate market value of $332,208.38 for the shares and a company share count of 42,214,106, meaning the blocks represent a small fraction of outstanding stock. The shares were acquired in a private placement on 01/13/2017 and were paid for in cash. The filing also discloses a prior sale of 6,000 shares by the same trust on 08/11/2025 for $300,000. The filer certifies no undisclosed material adverse information and includes the standard Rule 10b5-1 notice language.

William J. Link, a director of Tarsus Pharmaceuticals, Inc. (TARS), filed a Form 4 reporting a transaction dated 09/16/2025. The Form shows a disposition of 2,000 shares of common stock (transaction code G) at a reported price of $0. After the reported transaction, the filing states Mr. Link beneficially owns 141,332 shares directly and 10,446 shares indirectly through Link Family Enterprise, LP, of which he may be the controlling member. The form was signed by an attorney-in-fact on 09/18/2025.

Scott W. Morrison, a director of Tarsus Pharmaceuticals, received 1,334 shares on 09/15/2025 upon settlement of vested restricted stock units (RSUs). Each RSU converts into one share at vesting. After the transaction he directly beneficially owns 4,684 shares. He is also trustee of the Morrison-Minton Family 2004 Trust and, through that trust, indirectly beneficially owns an additional 6,016 shares. The RSUs vested in three equal annual installments on September 15 of 2023, 2024 and 2025, subject to continuous service.

William J. Link, Ph.D., a director of Tarsus Pharmaceuticals (TARS), reported a sale of company common stock on 09/08/2025. The filing shows 27,116 shares were sold (transaction code S) at a weighted-average price of $57 per share, with execution prices ranging from $56.66 to $57.45. After the sale, the reporting person beneficially owned 143,332 shares directly and an additional 10,446 shares indirectly through Link Family Enterprise, LP. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/10/2025. The filer notes availability of details on the number of shares sold at each price within the disclosed range.

Tarsus Pharmaceuticals (TARS) reported a Form 144 notice for a proposed sale of insider-held Class A shares. The filer notifies an intended sale of 27,116 Class A shares on Nasdaq, with an aggregate market value of $1,546,000 and approximately 42,214,106 shares outstanding, implying the proposed block represents about 0.064% of outstanding stock. The securities were acquired in a private placement on 12/13/2019 from William Link and were paid for in cash. The intended sale date listed is 09/08/2025. The filer states there are no sales in the past three months and affirms no undisclosed material adverse information.

RTW Investments, LP and Roderick Wong report beneficial ownership of 3,424,180 shares of Tarsus Pharmaceuticals common stock, representing 8.1% of the outstanding shares based on 42,014,237 shares outstanding as reported in the companys quarterly report dated April 24, 2025. The shares are held by the RTW Funds, for which RTW Investments is the investment adviser, and Dr. Wong reports the same aggregate holding on behalf of those funds.

The filing shows no sole voting or dispositive power (0 shares) and shared voting and dispositive power over the 3,424,180 shares. The Reporting Persons certify the securities are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer.

Bobak R. Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals (TARS), reported sales of common stock on 08/11/2025 as shown on this Form 4. The filing lists dispositions of 53,635 and 6,000 shares and shows a transaction price of $50 where indicated, with reported beneficial ownership of 818,106 shares following the transactions. The sales were effected automatically under a Rule 10b5-1 trading plan adopted December 12, 2024. Azamian is trustee of the Bobak Azamian Living Trust (established April 16, 2018) and has voting and dispositive power over the trust shares. The Form 4 was signed by an attorney-in-fact on 08/13/2025.